KIT and gastrointestinal stromal tumor: In conclusion, this analysis demonstrates that a significant proportion of quadruple–WT GIST patients are actually carrying pathologically relevant low-allele-fraction KIT mutations, that would benefit from TKI treatments both in the adjuvant and metastatic setting and that should be readily identified at the early diagnostic stage though implementation of appropriate next-generation-sequencing panels and addressing to national hub diagnostic centers.